All Clarivate websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.

More information on our cookie policy.

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
  • Special reports
    • Artificial intelligence
    • Coronavirus
    • IVDs on the rise
    • Top Biopharma Trends of 2021
    • Top Med-tech Trends of 2021
    • Premium reports
      • BioWorld Financings Reports
      • Disease Incidence & Prevalence Summaries

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Thursday, June 30, 2022
Home » Blogs » BioWorld MedTech Perspectives » No excuses, get an EHR!

BioWorld MedTech Perspectives
BioWorld MedTech Perspectives RSS FeedRSS

BioWorld MedTech / Imaging

No excuses, get an EHR!

July 20, 2012
By Amanda Pedersen
No Comments

An acquaintance of mine who, like me, has inflammatory bowel disease, received a call recently from her local hospital informing her they had lost her MRI images. They found them, but she is concerned they will have to retake them anyway because at this point her images are no longer current enough for the doctor to make an informed treatment decision.

This is a prime example of why all hospitals should use electronic health records (EHRs). At a time when health IT (HIT) companies are cropping up faster than Starbucks coffee shops, and the federal government is handing out incentive funds to those hospitals who use electronic records, there is truly no excuse for not having an EHR system in place.

Asking patients to retake an MRI simply because they can’t keep their records together is not only inconvenient for the patient but extremely inefficient for the hospital. Assuming this sort of thing happens regularly, these are dollars the hospital is flushing away that could be invested in an EHR system.

Sure, there are initial costs involved with installing a reliable EHR system, but many of these costs are reimbursable under the American Recovery and Reinvestment Act and most HIT companies are eager to guide clients through the meaningful use requirements. It makes the company look good and it recovers critical funds for the hospitals to put to other uses, like saving lives.

Just as one example, we recently reported in Medical Device Daily that a financially-strapped 319-bed county hospital in California went live on Medsphere Systems’ OpenVista open source EHR. That hospital is expected, according to Medsphere, to receive “substantially more” in federal reimbursement than the five-year costs to acquire the system. It makes sense not only from a patient care standpoint but from a financial perspective also.

Medsphere President/CEO Irv Lichtenwald called the move a compelling example of responsible decision-making, and I agree. “Especially in these troubled economic times, public hospitals can still improve care without making financial matters worse for local government,” Lichtenwald said.

And of course Medsphere is not alone in the HIT market, the firm has plenty of competitors, all more than happy to help private and public hospitals alike experience similar financial gains by implementing these invaluable electronic records systems.

You must login or register in order to post a comment.

Report Abusive Comment

Popular Stories

  • Free access to BioWorld coronavirus articles

    BioWorld

    The articles in this collection are from BioWorld’s ongoing coverage of the COVID-19 coronavirus outbreak. Note that we have added three critical tables which are...

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 29, 2022.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech's briefs for June 29.
  • Enhertu.png

    Swing low, sweet Enhertu: Astrazeneca, Daiichi ASCO data carry HER2 message home

    BioWorld
    The “showdown” at the American Society of Clinical Oncology (ASCO) meeting foreseen by one analyst between breast cancer drugs from Gilead Sciences Inc. and...
  • Novavax-COVID-19-vaccine-vial

    Novavax vaccine shows its chops

    BioWorld
    Given that Novavax Inc.’s COVID-19 vaccine will be a latecomer to the U.S. scene if it gets FDA authorization, it’s been cast in a supporting role to the lead...
black cortellis ad

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.

Subscribe
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Archives
    • Today's news
    • Search BioWorld Science
    • About
  • More
    • About
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
Follow Us

Copyright ©2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing